Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC

The prognosis of advanced non-small cell lung cancer (NSCLC) is poor; therefore, identifying novel treatment strategies for patients with NSCLC is important. The present study aimed to investigate the efficacy of apatinib plus docetaxel vs. docetaxel alone, as well as their effects on regulating aut...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Rong, Li, Tao, Hui, Kaiyuan, Chen, Zi, Wang, Nan, Wu, Xingping, Ge, Linyang, Zhou, Linfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533512/
https://www.ncbi.nlm.nih.gov/pubmed/32901884
http://dx.doi.org/10.3892/mmr.2020.11492

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533512/
https://www.ncbi.nlm.nih.gov/pubmed/32901884
http://dx.doi.org/10.3892/mmr.2020.11492

Ejemplares similares